| Autor: |
Ana Rodríguez-Carmona, Miguel Pérez Fontán, Susana Sangiao Alvarellos, Teresa García Falcón, María Lara Pena Bello, Andrés López Muñiz, Fernando Cordido |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Nefrología (English Edition), Vol 36, Iss 5, Pp 496-502 (2016) |
| Druh dokumentu: |
article |
| ISSN: |
2013-2514 |
| DOI: |
10.1016/j.nefroe.2016.11.011 |
| Popis: |
Background: Irisin is an adipomyokine with claimed anti-obesity and anti-diabetic effects. This hormone has been insufficiently studied in patients with advanced chronic kidney disease (CKD). Objective: To perform an exploratory analysis of serum irisin levels in patients undergoing different CKD treatments. Method: Following a cross-sectional design, we estimated serum levels of irisin in 95 patients with CKD managed conservatively (advanced CKD), with peritoneal dialysis (PD) or with haemodialysis, and compared our findings with a control group of 40 healthy individuals. We investigated the correlations between serum irisin and demographic, clinical, body composition and metabolic variables. Results: Irisin levels were lower in all the CKD groups than in the control group. The univariate analysis revealed limited correlations between irisin, on the one hand, and fat (but not lean) mass, glomerular filtration rate (GFR) and plasma albumin and bicarbonate, on the other. The multivariate analysis confirmed that advanced CKD patients managed conservatively (difference 111.1 ng/mL), with PD (25.9 ng/mL) or haemodialysis (61.4 ng/mL) (all p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
